Boston, MANCT07119229Now EnrollingIRB Ready

Emphysema or COPD Clinical Trial in Boston, MA

Access cutting-edge emphysema or copd treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Pulmair Medical, Inc.

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access emphysema or copd specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related emphysema or copd treatment provided free

Apply for This Boston Location

Check if you qualify for this emphysema or copd clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Emphysema or COPD Study in Boston

A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.

Sponsor: Pulmair Medical, Inc.

Who Can Participate

Inclusion Criteria

Signed Informed Consent.
Diagnosis of COPD/emphysema.
At least 22-years of age.
18 ≤ BMI ≤ 32.
6-minute walk Distance between 100-meters and 400-meters at baseline exam.
Stable disease with less than 10-mg prednisone (or equivalent) daily
Non-smoking for 4-months prior to screening interview (including tobacco, vaping, marijuana, etc.).
FEV1 between 15% and 50% of predicted value at baseline exam.
FEV1/FVC \<70%.
Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation \<-950 HU, as determined by CT core lab.
Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score (\< -950HU) as determined by CT core lab.
RV \> 175% of predicted value.
mMRC score ≥ 2.

Exclusion Criteria

1\. Currently participating in another clinical study that involves surgery, interventional or pharmaceutical treatment.. 2\. α-1 Antitrypsin deficiency 3. Women of child-bearing potential. 4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening. 5\. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention. 6\. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening. 7\. Clinically significant mucus production or chronic bronchitis. 8. Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6-months of screening. 9\. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR). 10\. Clinically significant bronchiectasis. 11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days. 12\. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \>45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3-months prior to screening visit). Note: the echocardiogram is not a required screening procedure. 13\. Suspected malignant pulmonary nodule or other lung cancer. 14. HRCT collected per CT scanning protocol within the last 6-months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:
Large bullae encompassing greater than 30% of either lung
Insufficient landmarks to evaluate the CT study using the software as it is intended
All lobes are less than 25% parenchyma diseased (\< -950 HU) 15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant. 16\. TLC \< 100% predicted at screening. 17. DLCO \< 15% or \> 50% of predicted value at screening. 18. PaCO2 \> 50 mm Hg at screening. 19. PaO2 \< 45 mm Hg in room air at screening. 20. Plasma cotinine level \> 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) \>2.5% at screening. 21\. Current diagnosis of substance abuse disorder. 22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder. 23\. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07119229) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Emphysema or COPD Treatment Options in Boston, MA

If you're searching for emphysema or copd treatment options in Boston, MA, this clinical trial (NCT07119229) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced emphysema or copd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all emphysema or copd clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Boston, MA

See all parkinsons disease clinical trials recruiting in Boston — not just this study.

Browse Parkinsons Disease Trials in Boston →

Browse More Trials by Condition

Parkinsons Disease TrialsCOPD TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA